Akebia Announces $50M Public Offering

Deal News | Mar 20, 2025 | Wilmer Cutler Pickering Hale and Dorr LLP

Akebia Announces $50M Public Offering

Akebia Therapeutics, Inc., a biopharmaceutical company dedicated to kidney disease treatment, has announced the pricing of its public offering of 25 million common shares at $2.00 per share, resulting in expected gross proceeds of $50 million prior to underwriting and other expenses. The underwriters retain a 30-day option to purchase an additional 3.75 million shares. The offering is advised by WilmerHale, with a legal team comprising Stuart Falber, Caroline Dotolo, Katharine Patterson, Rachael Joseph, and Whitley Horning.

Sectors

  • Biopharmaceuticals
  • Legal Advisory

Geography

  • United States – The primary geography involved is the United States as Akebia Therapeutics is based in the US and the public offering is being conducted there.

Industry

  • Biopharmaceuticals – Akebia Therapeutics is part of the biopharmaceutical industry, focusing on therapies for kidney disease.
  • Legal Advisory – WilmerHale is involved in the legal advisory industry, providing legal counsel for Akebia's public offering.

Financials

  • 50,000,000 – Gross proceeds expected from Akebia's public offering.
  • 2.00 – Public offering price per share for Akebia's common stock.
  • 25,000,000 – Number of shares offered in the public offering.
  • 3,750,000 – Additional shares available for underwriters to purchase.

Participants

NameRoleTypeDescription
Akebia Therapeutics, Inc.Target CompanyCompanyA biopharmaceutical company working on treatments for kidney disease.
Wilmer Cutler Pickering Hale and Dorr LLPLegal AdvisorCompanyA law firm advising Akebia on their public offering.
Stuart FalberLegal AdvisorPersonPart of the WilmerHale team advising Akebia Therapeutics.
Caroline DotoloLegal AdvisorPersonPart of the WilmerHale team advising Akebia Therapeutics.
Katharine PattersonLegal AdvisorPersonPart of the WilmerHale team advising Akebia Therapeutics.
Rachael JosephLegal AdvisorPersonPart of the WilmerHale team advising Akebia Therapeutics.
Whitley HorningLegal AdvisorPersonPart of the WilmerHale team advising Akebia Therapeutics.